Wordt geladen...
Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies
The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib has been approved for years as a first-line therapy for patients harboring EGFR-sensitizing mutations. With the promising implementation of immunotherapeutic strategies for the treatment of lung cancer, there is a gr...
Bewaard in:
| Gepubliceerd in: | Cell Death Dis |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5059888/ https://ncbi.nlm.nih.gov/pubmed/27685624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2016.297 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|